The RNA Therapeutics Core under construction at the GCTI is dedicated to supplying high quality custom circular RNA to the MGB research community and beyond. In addition to providing stock circRNA encoding commonly used proteins for any application, the Core will take custom synthesis requests to generate circRNA encoding nearly any gene of interest. The Core plans to offer GMP-grade material at scales required for first in human clinical trials to facilitate the translation of discoveries from bench to bedside, in addition to lipid nanoparticle formulations. With a suite of cutting-edge RNA technology solutions including machine learning-guided sequence design, the RNA Therapeutics Core stands ready to partner for circRNA research and development.